clinical trial · NCT06168734
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
Venatorx Pharmaceuticals, Inc.·phase3·withdrawn
Ventilator-associated PneumoniaHospital-acquired PneumoniaCefepime-taniborbactamMeropenem
brief summary
This is a Phase 3, randomized, multicenter, double-blind, non-inferiority study to evaluate the efficacy and safety of cefepime-taniborbactam compared to meropenem in patients ≥ 18 years of age with ventilated HABP or VABP.
started
Jun 1, 2025
primary completion
Jun 1, 2027
completion
Dec 1, 2027
last updated
Jun 8, 2025
official title
A Phase 3 Study to Evaluate Cefepime-taniborbactam Compared to Meropenem in Adults With Ventilator Associated Bacterial Pneumonia (VABP) or Ventilated Hospital Acquired Bacterial Pneumonia (vHABP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol